Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
20096458
DOI
10.1016/j.leukres.2009.12.018
PII: S0145-2126(09)00600-6
Knihovny.cz E-resources
- MeSH
- B-Lymphocytes metabolism pathology MeSH
- Centrosome metabolism pathology MeSH
- Adult MeSH
- Fluorescent Antibody Technique MeSH
- In Situ Hybridization, Fluorescence MeSH
- Karyotyping MeSH
- Middle Aged MeSH
- Humans MeSH
- Mitosis * MeSH
- Multiple Myeloma genetics pathology MeSH
- Plasma Cells metabolism pathology MeSH
- Prognosis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Centrosome amplification (CA) as a potential marker of mitotic disruptions in multiple myeloma (MM) was investigated in two populations of B-cell lineage: B-cells and plasma cells (PCs). Using immunofluorescent staining, it was shown that CA in B-cells is present in 3.2+/-2.5% in healthy donors versus 9.9+/-7.9% in MM patients (p<0.0001). Based on the calculated threshold value of CA in B-cells, 37% (14/38) of MM patients were positive. There was no significant correlation between CA-positive MM cases (based on PC samples evaluation) and the occurrence of cytogenetic abnormalities in PCs, including del(13)(q14), del(17)(p13), gain(1)(q21) and hyperdiploidy.
References provided by Crossref.org
Centrosome associated genes pattern for risk sub-stratification in multiple myeloma
